XXXX as long-term secondary prevention after @entity385 .

@entity1 @entity7784 @entity8393 @entity64 @entity753 @entity8 @entity2299 @entity177 @entity1188 @entity412 @entity165 @entity385
BACKGROUND: It is sometimes difficult to choose anti-thrombotic agents for secondary prevention in @entity64 @entity1 at high bleeding risk. Recently, @entity7784 ( @entity8393 ) was reported to reduce the recurrence of @entity64 in @entity753 @entity1 without increasing hemorrhagic risk. In this study, we investigated the features of recurrent @entity64 @entity1 during @entity8393 medication as secondary @entity64 prevention. METHODS: Following the approval of the ethical committee, @entity64 @entity1 in the outpatient clinic were consecutively screened and @entity1 who continuously take @entity8393 were enrolled in this study (n   =   71, average age 69.7 yo). Blood sample data was adopted from the latest visit or the admission at the @entity64 recurrence. According to the previous @entity64 history, all @entity1 were classified into the @entity64 ( @entity64 ) group (n   =   10) and the @entity385 , including asymptomatic @entity1188 , (IS) group (n   =   61). RESULT: Any @entity64 recurrence was not observed in the @entity64 group. Whereas, @entity385 was observed in 6 @entity1 in the IS group, although there was no @entity64 recurrence. Recurrent @entity64 @entity1 showed the higher serum level of @entity165 or the @entity8 . The @entity64 subtype of @entity1 were 2 @entity64 , 3 @entity1188 (two were compromised with @entity177 and one had insufficient amount of @entity8393 ) and one @entity1188 (who showed high @entity412 level). CONCLUSION: @entity64 was not occurred in our observation of @entity8393 prescribed @entity1 . The clinical features of recurrent @entity64 @entity1 were the existing complications of @entity2299 and @entity8 .
